Movantik® (naloxegol) – New Warning

- On August 22, 2016, the FDA approved a new update to the *Warnings and Precautions* section of the Movantik (naloxegol) drug label, regarding severe abdominal pain and/or diarrhea.
    - Movantik is indicated for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
- Reports of severe abdominal pain and/or diarrhea have been reported, some of which resulted in hospitalization. Most of the cases of severe abdominal pain were reported in patients taking the 25 mg dosage. Symptoms generally occurred within a few days of initiation of Movantik.
- Patients should be monitored for the development of abdominal pain and/or diarrhea. Movantik should be discontinued if severe symptoms occur. Movantik may be restarted at 12.5 mg once daily, if appropriate.
- Other warnings and precautions of Movantik include opioid withdrawal and gastrointestinal perforation.
- In addition, the Movantik drug label has been updated with information regarding the administration of crushed tablets mixed in water given orally or via nasogastric tube.
    - Previously, the instructions for Movantik stated to swallow the tablets whole, do not crush or chew.